ArticleJournal of inflammation research2024
A Longitudinal Dynamic Change in LMR Can Be a Biomarker for Recurrence in Fusobacterium Nucleatum-Positive Colorectal Cancer Patients.
Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel immune-nutritional prognostic ratio predicts long-term survival in stage I-III colorectal cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study assessed lymphocyte-to-monocyte ratio (LMR) changes to predict postoperative recurrence in Fusobacterium nucleatum-positive (Fn-positive) CRC patients. Patients and Methods: Clinical information and paraffin tissue specimens were collected from a retrospective cohort of 332 patients. The abundance of Fn in tumor tissue was measured using a quantitative polymerase chain reaction. We evaluated the prognostic value and diagnostic performance of the dynamic changes of LMR from pre-operative to post-treatment (pr-LMR-po) and the dynamic alterations of LMR from pre-operative to post-treatment to pre-end of follow-up (pr-LMR-f) in predicting recurrence in Fn-positive CRC. Results: In the total cohort and adjuvant therapy group cohort, pr-LMR-po independently predicted recurrence-free survival in Fn-positive CRC patients. In the adjuvant therapy group, pr-LMR-po (High-High vs Low-Low: HR: 3.896, 95% CI: 1.503-10.095, p=0.005) was particularly significant. Meanwhile, pr-LMR-f can serve as a predictive biomarker for Fn-positive CRC recurrence, especially in the adjuvant therapy group cohort where the c-statistic for pr-LMR-f was 0.825 (95% CI: 0.804-0.8251), with a sensitivity of 83.6% and a specificity of 79.3%. Compared to the overall adjuvant therapy group cohort, the prognostic performance of pr-LMR-f was superior in the Fn-positive CRC adjuvant therapy group cohort (AUC: 0.825 VS 0.711). Finally, we constructed a prediction model combining pr-LMR-f and CEA. After internal validation using the bootstrap resampling, the model had an AUC of 0.9295, a sensitivity of 94%, and a specificity of 72.7% in the Fn-positive CRC adjuvant therapy group cohort. Conclusion: This study found that pr-LMR-po predicts Fn-positive CRC prognosis, and pr-LMR-f may predict Fn-positive CRC recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.